Isle of Skye

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Retrieved on: 
Lundi, juin 10, 2024
Isle of Skye, Glaucoma, Patient, IOP, CB1, Ocular hypertension, OHT, SAN, Chair, Eye, OE, Pharmaceutical industry

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, announced that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma ("POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure (“IOP”). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027. Skye’s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing in Q3 2024.

Key Points: 
  • Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027.
  • Skye’s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing in Q3 2024.
  • With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline,” said Punit Dhillon, Skye’s CEO and Chair.
  • We will look forward to sharing updates on this clinical program and advancing Nimacimab through to data in 2025.”

Manly Bands Embraces Tradition with Timeless Celtic Style

Retrieved on: 
Vendredi, mars 15, 2024
Isle of Skye, Longevity, BYOB, McCartin, Collection, Love, Onyx, Celtic knot, Tungsten, Platinum, Individual, Jewellery

LINDON, Utah, March 15, 2024 /PRNewswire/ -- Manly Bands, the leading destination for unique and stylish men's rings, proudly showcases their Celtic Ring Collection. Inspired by the rich heritage and intricate designs of Celtic culture, these rings offer a perfect blend of tradition and contemporary style.

Key Points: 
  • Inspired by the rich heritage and intricate designs of Celtic culture, these rings offer a perfect blend of tradition and contemporary style.
  • Incorporating onyx, black diamonds, and precious metals into timeless claddagh designs, Manly Bands maintains Celtic heritage while introducing 21st century elements into a timeless ring.
  • Through the introduction of tartan fabrics patterned after specific Celtic families, Manly Bands creates a product that proudly displays familial ties and heritage.
  • "At Manly Bands, we understand that wedding bands are more than just accessories - they are symbols of love and commitment," said Michelle Luchese, co-founder of Manly Bands.

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Retrieved on: 
Lundi, février 26, 2024
OTCQB, SAN, IOP, Glaucoma, OE, Blood, Obesity, OHT, Eye, Database, Safety, Biomarker, CB1, Ocular hypertension, Patient, THC, Hyperaemia, Trial of the century, Isle of Skye, Pharmaceutical industry

All treated patients completed the study, with no early discontinuations due to adverse events.

Key Points: 
  • All treated patients completed the study, with no early discontinuations due to adverse events.
  • “Because this trial completed enrollment ahead of schedule, our initially intended interim data report based on partial enrollment is unnecessary.
  • Skye is evaluating SBI-100 OE’s ability to lower IOP, safety and relevant biomarkers in patients with POAG or OHT.
  • Low rate of hyperaemia (red eyes) of 8.4% compared to higher rates in other leading classes of glaucoma drugs.

Standard Uranium Outlines 2024 Exploration Plans & Granting of Stock Options & RSUs

Retrieved on: 
Vendredi, janvier 12, 2024
Completeness, Athabasca, TDEM, Weather, Thunderbird, Gunnar, Hand, Tourmaline, Employment, Option, Uranium, Tropical cyclone, Java, Consultant, ALS, Term sheet, First Nations, Radioactive decay, 3D, EM, News, Arrow, Isle of Skye, Uranium mining

2024 will be the most ambitious year of exploration activities for the Company to date (Figure 2).

Key Points: 
  • 2024 will be the most ambitious year of exploration activities for the Company to date (Figure 2).
  • Jon Bey, CEO and Chairman of the Company, stated: “2024 will be the Company’s most comprehensive and exciting exploration season to date.
  • Standard Uranium is well underway in JV discussions to unlock the potential for discovery at Atlantic in 2024.
  • Standard has engaged all key vendors to execute the 2024 exploration plans across all projects despite competitive conditions in the industry.

™PAW Patrol: Adventure Play Helps Save The Day at The Henry Ford Museum of American Innovation

Retrieved on: 
Mardi, janvier 9, 2024
Mountain, Turtle, Humanities, Taste, Snow, SPIN, PAW, Paramount Global Content Distribution, Multimedia, Partnership, Chase, Museum, Spin, PAW Patrol, Rubble, Isle of Skye

DEARBORN, Mich., Jan. 9, 2024 /PRNewswire/ -- Kids and families can now play and save the day with the heroic PAW Patrol pups, at the brand-new PAW Patrol: Adventure Play exhibit, open to the public February 17, 2024, at the Henry Ford Museum of American Innovation.

Key Points: 
  • DEARBORN, Mich., Jan. 9, 2024 /PRNewswire/ -- Kids and families can now play and save the day with the heroic PAW Patrol pups, at the brand-new PAW Patrol: Adventure Play exhibit, open to the public February 17, 2024, at the Henry Ford Museum of American Innovation.
  • The hands-on, immersive PAW Patrol: Adventure Play exhibit is a fun way for the whole family to learn bravery and heroism, with exciting stories.
  • The whole family will learn how to combine their skills to problem-solve together and save the day.
  • PAW Patrol: Adventure Play was produced by The Children's Museum of Indianapolis in partnership with Nickelodeon.

SHIH TZU "COMET" WINS BEST IN SHOW AT 23rd AKC® NATIONAL CHAMPIONSHIP PRESENTED BY ROYAL CANIN

Retrieved on: 
Mardi, janvier 2, 2024
Carbon, Boxer, Okie, National championship, Dera, Health, RNC, Dot, Legend, Dog, Luke, CGC, PDS, Whippet, Ashes, Crusader, Royal Canin, German Shepherd, Border Collie, Bolt (2008 film), Bulldog, ABC, Cavalier, Bedlington Terrier, Excellent, Scarlet, Venture, NOHS, Breed, Southpaw, Open, Throne, TKI, MFG, Norwegian Buhund, CDX, Television, Orange County Convention Center, Poodle, Lexi, Onyx, FITB, Magic, AKC, Shetland Sheepdog, Golden, Pot, Temperament, MD, High Times, Best in Show, MJC, Isle of Skye

ORLANDO, Fla., Jan. 2, 2024 /PRNewswire/ -- GCHP CH Hallmark Jolei Out Of This World, a Shih Tzu known as "Comet" triumphed over more than 5,700 competitors to earn a $50,000 cash prize and the title of Best in Show at the AKC® National Championship Presented by Royal Canin, held December 16-17, 2023 at the Orange County Convention Center in Orlando, FL. "Comet," owned by Bonnie J Miller, Susan Carter, Luke & Diane Ehricht of Monclova, OH and bred by Luke & Diane Ehricht, was crowned "America's National Champion" by Best in Show judge Mr. Clay Coady after a weekend of intense canine competition. The winner is America's only National Champion.

Key Points: 
  • CH Von Hawes Forever Forward, a Rottweiler known as "Granger," owned and bred by Peter Hawes & Kathleen Hawes & Erin Maureen Foreman of New Castle, CA.
  • The 2023 AKC® Obedience Classic and the AKC® Agility Invitational presented by YuMOVE were held in conjunction with the AKC® National Championship.
  • Luke and Diane Ehricht were presented with the 2023 AKC Breeder of the Year Award for Hallmark Jolei Shih Tzu at the AKC National Championship on Saturday, December 16, 2023.
  • Click here to download images and video from the AKC National Championship.

Skye Fund III Issues Letter Regarding Opposition to SomaLogic’s Proposed Merger with Standard BioTools

Retrieved on: 
Mercredi, décembre 20, 2023
Thermo Fisher Scientific, Science, SomaLogic, Partnership, Proteomics, Drug development, Standard BioTools, Physician, Research, Acquisition, DNA, Common stock, Isle of Skye, Knowledge, Letter, Genomics, Optimism, Security (finance)

BALTIMORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Skye Fund III, which together with its affiliates, owns approximately 3.4 million shares of SomaLogic, Inc., (NASDAQ: SLGC) (the “Company”) and has been an investor in the Company for 20 years, today issued an open letter to the Company’s shareholders regarding its opposition to the Company’s proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (NASDAQ: LAB) and its intention to vote AGAINST the Proposed Merger at the upcoming special meeting of shareholders scheduled for January 4, 2024.

Key Points: 
  • After reviewing both the Company’s and Madryn Asset Management, LP’s (“Madryn”) proxy materials with respect to the proposed merger (the “Proposed Merger”) between the Company and Standard BioTools, Inc. (NASDAQ: LAB) (“Standard BioTools”), as well as other publicly available information, we conclude that the Proposed Merger is antithetical to the interests of SomaLogic shareholders.
  • Which brings us to our principal objection to the Proposed Merger – it grossly undervalues the potential of SomaLogic.
  • We also agree with Madryn that there are several other concerning issues with the Proposed Merger.
  • For all of these reasons, Skye will be voting AGAINST the Proposed Merger.

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

Retrieved on: 
Mardi, novembre 28, 2023
IOP, Patient, Hyperaemia, Risk, Trial of the century, Blood, MD, SAN, THC, Eye, Isle of Skye, Intraocular pressure, OHT, Ocular hypertension, OTCQB, CB1, Biomarker, OE, Safety, Non-Euclidean geometry, Glaucoma, Pharmaceutical industry

SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.

Key Points: 
  • SBI-100 OE is a synthetic prodrug of tetrahydrocannabinol (“THC”) that is able to bind and activate CB1 receptors in key ocular tissues.
  • We are advancing the next generation of investigational drugs targeting the endocannabinoid system’s CB1 receptor,” said Punit Dhillon, Skye’s CEO and Chairman.
  • “This Phase 2 study provides an avenue to confirm IOP-lowering ability and advance the potential for SBI-100 OE in treating ophthalmic disorders.
  • In preclinical studies involving three different species, SBI-100 OE lowered IOP to a level and duration that compared favorably to the standard of care for treating glaucoma.

Spin Master Delivers The Magic with Four Toys Named to Walmart's 2023 Top Toys List

Retrieved on: 
Mardi, août 22, 2023
Monkey see, monkey do, Magic, Mighty, PAW, Walmart, Dollhouse, DreamWorks Animation, Isle of Skye, Pet, TSX, Ecosystem, System, Gabby, Toy

TORONTO, Aug. 22, 2023 /PRNewswire/ - Spin Master Corp. (TSX: TOY) ( www.spinmaster.com ), a leading children's entertainment company, is delivering the magic this holiday season with four toys being named to Walmart's highly-anticipated 2023 Top Toys List .

Key Points: 
  • TORONTO, Aug. 22, 2023 /PRNewswire/ - Spin Master Corp. (TSX: TOY) ( www.spinmaster.com ), a leading children's entertainment company, is delivering the magic this holiday season with four toys being named to Walmart's highly-anticipated 2023 Top Toys List .
  • Walmart's 2023 Top Toys List celebrates this year's most-wanted toys for kids (and kids at heart!)
  • of all ages, making it affordable, easy and fun to shop and spread cheer all season long.
  • "Spin Master's 2023 toy portfolio reaffirms our reputation of continuous innovation, coupled with incredible quality and play value that extends beyond the holiday season."

Roll Out the Red Carpet for Spin Master's PAW Patrol: The Mighty Movie™ Toy Collection

Retrieved on: 
Mardi, août 1, 2023
Aircraft, Ryder, Music, PAW Patrol, Life, PAW, Rotation, Aircraft carrier, SRP, Android, Paramount Pictures, IOS, Spin Master, Nickelodeon Movies, Isle of Skye, Collection, Chase, Sound, TSX, Toy, Film industry

"Packed with jaw-dropping transformations, the PAW Patrol: The Mighty Movie toy collection will spark limitless imaginative play," said Chris Beardall, Spin Master's President of Toys and Chief Commercial Officer.

Key Points: 
  • "Packed with jaw-dropping transformations, the PAW Patrol: The Mighty Movie toy collection will spark limitless imaginative play," said Chris Beardall, Spin Master's President of Toys and Chief Commercial Officer.
  • The PAW Patrol: The Mighty Movie toy collection includes a wide range of toys from vehicles and playsets to plush and roleplay for preschoolers to play out their own mighty missions.
  • Available August 1, 2023 at major retailers, highlights include:
    Skye's Mighty Movie JetTM: With a leading role in PAW Patrol: The Mighty Movie, small but mighty Skye takes to the skies with her all-new Mighty Movie Jet.
  • Join Ryder and his crew of pups on their mighty adventures in PAW Patrol: The Mighty Movie coming to theaters September 29, 2023.